| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 68 | 2025 | 5097 | 4.010 |
Why?
|
| Anti-HIV Agents | 29 | 2025 | 1324 | 3.700 |
Why?
|
| Ritonavir | 17 | 2021 | 137 | 1.770 |
Why?
|
| Infectious Disease Transmission, Vertical | 19 | 2024 | 472 | 1.590 |
Why?
|
| Nevirapine | 11 | 2019 | 146 | 1.470 |
Why?
|
| Viral Load | 26 | 2025 | 819 | 1.470 |
Why?
|
| HIV-1 | 18 | 2024 | 1260 | 1.450 |
Why?
|
| Lopinavir | 18 | 2021 | 137 | 1.360 |
Why?
|
| Child Development | 4 | 2024 | 93 | 1.300 |
Why?
|
| Infant | 35 | 2024 | 2244 | 1.300 |
Why?
|
| Pregnancy Complications, Infectious | 7 | 2024 | 529 | 1.290 |
Why?
|
| Female | 63 | 2025 | 9103 | 1.260 |
Why?
|
| Humans | 75 | 2025 | 14537 | 1.240 |
Why?
|
| Child, Preschool | 33 | 2025 | 1748 | 1.210 |
Why?
|
| Anti-Retroviral Agents | 14 | 2024 | 551 | 1.110 |
Why?
|
| Male | 52 | 2025 | 6754 | 1.100 |
Why?
|
| Infant, Newborn | 24 | 2024 | 1479 | 1.060 |
Why?
|
| HIV Protease Inhibitors | 10 | 2018 | 92 | 1.020 |
Why?
|
| South Africa | 44 | 2024 | 7596 | 1.010 |
Why?
|
| Benzoxazines | 10 | 2021 | 123 | 0.990 |
Why?
|
| Developmental Disabilities | 2 | 2016 | 22 | 0.960 |
Why?
|
| Child | 32 | 2025 | 2242 | 0.930 |
Why?
|
| Breast Feeding | 3 | 2020 | 120 | 0.870 |
Why?
|
| Dideoxynucleosides | 3 | 2020 | 29 | 0.830 |
Why?
|
| Antiretroviral Therapy, Highly Active | 8 | 2017 | 472 | 0.750 |
Why?
|
| Prenatal Exposure Delayed Effects | 2 | 2020 | 19 | 0.710 |
Why?
|
| Neonatal Screening | 2 | 2021 | 24 | 0.700 |
Why?
|
| Pregnancy | 16 | 2024 | 1862 | 0.690 |
Why?
|
| Cohort Studies | 16 | 2025 | 967 | 0.680 |
Why?
|
| Hearing Tests | 1 | 2021 | 4 | 0.680 |
Why?
|
| Stavudine | 3 | 2018 | 78 | 0.670 |
Why?
|
| Bone Density | 6 | 2022 | 107 | 0.670 |
Why?
|
| Lipids | 4 | 2018 | 81 | 0.630 |
Why?
|
| Drug Substitution | 1 | 2018 | 33 | 0.570 |
Why?
|
| Early Medical Intervention | 1 | 2018 | 7 | 0.560 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2016 | 7 | 0.480 |
Why?
|
| Drug Therapy, Combination | 11 | 2018 | 279 | 0.480 |
Why?
|
| Calcaneus | 3 | 2022 | 14 | 0.470 |
Why?
|
| Early Diagnosis | 3 | 2021 | 82 | 0.460 |
Why?
|
| Atazanavir Sulfate | 1 | 2015 | 10 | 0.460 |
Why?
|
| Treatment Outcome | 13 | 2025 | 889 | 0.460 |
Why?
|
| Prospective Studies | 6 | 2024 | 1160 | 0.440 |
Why?
|
| Tenofovir | 3 | 2025 | 171 | 0.430 |
Why?
|
| Emtricitabine | 2 | 2025 | 78 | 0.430 |
Why?
|
| Case-Control Studies | 9 | 2022 | 480 | 0.420 |
Why?
|
| HIV | 4 | 2018 | 380 | 0.410 |
Why?
|
| Alkynes | 10 | 2021 | 117 | 0.390 |
Why?
|
| Cyclopropanes | 10 | 2021 | 123 | 0.390 |
Why?
|
| Drug Resistance, Viral | 5 | 2015 | 278 | 0.360 |
Why?
|
| Epilepsy, Absence | 1 | 2011 | 2 | 0.360 |
Why?
|
| Oxidoreductases, N-Demethylating | 1 | 2011 | 6 | 0.360 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2011 | 8 | 0.360 |
Why?
|
| Premature Birth | 2 | 2022 | 80 | 0.350 |
Why?
|
| Polymerase Chain Reaction | 5 | 2020 | 260 | 0.350 |
Why?
|
| Cross-Sectional Studies | 10 | 2022 | 1422 | 0.350 |
Why?
|
| Body Composition | 3 | 2018 | 153 | 0.340 |
Why?
|
| CD4 Lymphocyte Count | 8 | 2025 | 656 | 0.340 |
Why?
|
| Follow-Up Studies | 4 | 2018 | 370 | 0.310 |
Why?
|
| Infant, Newborn, Diseases | 2 | 2020 | 73 | 0.280 |
Why?
|
| Bone and Bones | 2 | 2020 | 38 | 0.280 |
Why?
|
| Sustained Virologic Response | 2 | 2019 | 22 | 0.280 |
Why?
|
| HIV Seropositivity | 2 | 2022 | 265 | 0.280 |
Why?
|
| Longitudinal Studies | 8 | 2022 | 435 | 0.280 |
Why?
|
| Mothers | 2 | 2020 | 195 | 0.280 |
Why?
|
| Alanine | 2 | 2025 | 31 | 0.270 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2024 | 151 | 0.260 |
Why?
|
| Adenine | 2 | 2025 | 91 | 0.260 |
Why?
|
| Psychomotor Performance | 2 | 2016 | 12 | 0.250 |
Why?
|
| Malnutrition | 2 | 2017 | 56 | 0.240 |
Why?
|
| Communication | 2 | 2016 | 57 | 0.240 |
Why?
|
| Bone Remodeling | 3 | 2021 | 11 | 0.230 |
Why?
|
| Cobicistat | 1 | 2025 | 3 | 0.230 |
Why?
|
| Receptors, IgG | 2 | 2022 | 28 | 0.220 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2024 | 4 | 0.210 |
Why?
|
| Amides | 1 | 2024 | 8 | 0.210 |
Why?
|
| Adolescent | 5 | 2025 | 2985 | 0.210 |
Why?
|
| Cytochrome P-450 CYP2B6 | 2 | 2016 | 16 | 0.210 |
Why?
|
| Infection Control | 1 | 2024 | 31 | 0.210 |
Why?
|
| Ultrasonography | 3 | 2022 | 77 | 0.210 |
Why?
|
| Cross Infection | 1 | 2024 | 52 | 0.200 |
Why?
|
| Receptors, CCR5 | 1 | 2024 | 54 | 0.200 |
Why?
|
| Piperazines | 1 | 2024 | 82 | 0.200 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2024 | 85 | 0.200 |
Why?
|
| Pyridones | 1 | 2024 | 100 | 0.200 |
Why?
|
| HIV Protease | 2 | 2015 | 22 | 0.200 |
Why?
|
| Hospitals | 2 | 2021 | 103 | 0.200 |
Why?
|
| Streptococcal Vaccines | 1 | 2023 | 47 | 0.190 |
Why?
|
| Microbiota | 1 | 2023 | 30 | 0.190 |
Why?
|
| Tuberculosis, Pulmonary | 2 | 2020 | 324 | 0.190 |
Why?
|
| Chorioamnionitis | 1 | 2022 | 10 | 0.190 |
Why?
|
| Streptococcus agalactiae | 1 | 2023 | 202 | 0.180 |
Why?
|
| DNA, Viral | 2 | 2022 | 165 | 0.170 |
Why?
|
| AIDS-Related Opportunistic Infections | 2 | 2016 | 195 | 0.170 |
Why?
|
| Streptococcal Infections | 1 | 2023 | 184 | 0.170 |
Why?
|
| Hearing | 1 | 2021 | 3 | 0.170 |
Why?
|
| Otoacoustic Emissions, Spontaneous | 1 | 2021 | 3 | 0.170 |
Why?
|
| Viremia | 3 | 2016 | 66 | 0.170 |
Why?
|
| Algorithms | 1 | 2021 | 106 | 0.170 |
Why?
|
| Problem Behavior | 1 | 2020 | 6 | 0.160 |
Why?
|
| Rifampin | 2 | 2020 | 197 | 0.160 |
Why?
|
| Anthropometry | 2 | 2018 | 102 | 0.160 |
Why?
|
| Language Development | 1 | 2020 | 4 | 0.160 |
Why?
|
| Cognition | 1 | 2020 | 75 | 0.160 |
Why?
|
| Neuropsychological Tests | 1 | 2020 | 55 | 0.160 |
Why?
|
| Mutation, Missense | 3 | 2015 | 65 | 0.160 |
Why?
|
| Mitochondria | 1 | 2019 | 12 | 0.150 |
Why?
|
| DNA, Mitochondrial | 1 | 2019 | 31 | 0.150 |
Why?
|
| Epigenesis, Genetic | 1 | 2019 | 17 | 0.150 |
Why?
|
| HIV Seronegativity | 1 | 2019 | 52 | 0.150 |
Why?
|
| Sequence Analysis, DNA | 3 | 2015 | 181 | 0.150 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2021 | 198 | 0.150 |
Why?
|
| Educational Status | 1 | 2019 | 68 | 0.150 |
Why?
|
| Quality of Life | 1 | 2020 | 177 | 0.140 |
Why?
|
| Lipodystrophy | 1 | 2018 | 7 | 0.140 |
Why?
|
| Growth | 1 | 2018 | 14 | 0.140 |
Why?
|
| Clinical Protocols | 1 | 2018 | 26 | 0.140 |
Why?
|
| Genotype | 3 | 2021 | 442 | 0.140 |
Why?
|
| Adult | 7 | 2024 | 5913 | 0.140 |
Why?
|
| Aging | 1 | 2018 | 109 | 0.130 |
Why?
|
| Secondary Prevention | 1 | 2017 | 20 | 0.130 |
Why?
|
| Bone Development | 1 | 2016 | 19 | 0.130 |
Why?
|
| Problem Solving | 1 | 2016 | 3 | 0.130 |
Why?
|
| Child of Impaired Parents | 1 | 2016 | 9 | 0.130 |
Why?
|
| Body Weights and Measures | 1 | 2016 | 17 | 0.130 |
Why?
|
| Diet | 1 | 2017 | 109 | 0.120 |
Why?
|
| Zidovudine | 1 | 2016 | 59 | 0.120 |
Why?
|
| Truth Disclosure | 1 | 2016 | 18 | 0.120 |
Why?
|
| Drug Administration Schedule | 1 | 2016 | 156 | 0.120 |
Why?
|
| RNA, Viral | 5 | 2019 | 303 | 0.120 |
Why?
|
| Prevalence | 2 | 2017 | 1192 | 0.120 |
Why?
|
| Central Nervous System | 1 | 2016 | 11 | 0.120 |
Why?
|
| Lamivudine | 2 | 2013 | 89 | 0.120 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 1 | 2015 | 20 | 0.110 |
Why?
|
| Absorptiometry, Photon | 3 | 2022 | 85 | 0.110 |
Why?
|
| Medication Adherence | 2 | 2013 | 151 | 0.110 |
Why?
|
| Age Factors | 4 | 2018 | 370 | 0.110 |
Why?
|
| HIV Reverse Transcriptase | 1 | 2014 | 41 | 0.110 |
Why?
|
| Risk Factors | 2 | 2016 | 1475 | 0.110 |
Why?
|
| Preventive Health Services | 1 | 2014 | 17 | 0.110 |
Why?
|
| Chemoprevention | 1 | 2014 | 33 | 0.100 |
Why?
|
| Urban Population | 1 | 2016 | 257 | 0.100 |
Why?
|
| Exercise | 1 | 2016 | 205 | 0.100 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2014 | 198 | 0.100 |
Why?
|
| Retrospective Studies | 4 | 2021 | 799 | 0.100 |
Why?
|
| Antitubercular Agents | 2 | 2020 | 322 | 0.100 |
Why?
|
| HIV Antibodies | 1 | 2015 | 247 | 0.100 |
Why?
|
| Time Factors | 4 | 2018 | 507 | 0.100 |
Why?
|
| HIV-Associated Lipodystrophy Syndrome | 1 | 2012 | 8 | 0.100 |
Why?
|
| Surveys and Questionnaires | 3 | 2024 | 563 | 0.090 |
Why?
|
| Drug Combinations | 2 | 2024 | 42 | 0.090 |
Why?
|
| Homozygote | 1 | 2011 | 61 | 0.090 |
Why?
|
| Treatment Failure | 3 | 2018 | 175 | 0.090 |
Why?
|
| Immunoglobulin G | 2 | 2023 | 231 | 0.090 |
Why?
|
| Polymorphism, Genetic | 1 | 2011 | 99 | 0.090 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2011 | 176 | 0.080 |
Why?
|
| Pyrimidinones | 1 | 2010 | 24 | 0.080 |
Why?
|
| BCG Vaccine | 1 | 2009 | 20 | 0.080 |
Why?
|
| Pregnancy Outcome | 2 | 2022 | 117 | 0.080 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2009 | 33 | 0.070 |
Why?
|
| DNA Methylation | 2 | 2019 | 19 | 0.070 |
Why?
|
| Biomarkers | 2 | 2021 | 327 | 0.070 |
Why?
|
| Body Weight | 2 | 2024 | 111 | 0.070 |
Why?
|
| Growth Disorders | 2 | 2019 | 56 | 0.070 |
Why?
|
| Alleles | 2 | 2021 | 143 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2018 | 150 | 0.060 |
Why?
|
| Quinolones | 1 | 2025 | 7 | 0.060 |
Why?
|
| Drug Monitoring | 2 | 2016 | 55 | 0.060 |
Why?
|
| Thailand | 1 | 2024 | 26 | 0.050 |
Why?
|
| Hand Hygiene | 1 | 2024 | 3 | 0.050 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2024 | 17 | 0.050 |
Why?
|
| Young Adult | 2 | 2024 | 2498 | 0.050 |
Why?
|
| Hygiene | 1 | 2024 | 23 | 0.050 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2024 | 48 | 0.050 |
Why?
|
| United States | 1 | 2024 | 132 | 0.050 |
Why?
|
| Uganda | 1 | 2024 | 197 | 0.050 |
Why?
|
| Vaccines, Combined | 1 | 2023 | 34 | 0.050 |
Why?
|
| Mouth | 1 | 2023 | 8 | 0.050 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2023 | 18 | 0.050 |
Why?
|
| Immunity, Maternally-Acquired | 1 | 2023 | 40 | 0.050 |
Why?
|
| Seroepidemiologic Studies | 1 | 2023 | 109 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2024 | 225 | 0.050 |
Why?
|
| Africa | 1 | 2024 | 376 | 0.050 |
Why?
|
| Gene Duplication | 1 | 2022 | 13 | 0.050 |
Why?
|
| Placenta | 1 | 2022 | 44 | 0.050 |
Why?
|
| Birth Weight | 1 | 2022 | 80 | 0.050 |
Why?
|
| Vaccines, Conjugate | 1 | 2023 | 171 | 0.050 |
Why?
|
| Antibodies, Bacterial | 1 | 2023 | 153 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2022 | 60 | 0.050 |
Why?
|
| DNA Copy Number Variations | 1 | 2021 | 22 | 0.040 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2022 | 101 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2012 | 106 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 244 | 0.040 |
Why?
|
| Kinetics | 1 | 2020 | 65 | 0.040 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 284 | 0.040 |
Why?
|
| Biological Availability | 1 | 2020 | 43 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2020 | 31 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 61 | 0.040 |
Why?
|
| Animals | 4 | 2018 | 1081 | 0.040 |
Why?
|
| CpG Islands | 1 | 2019 | 6 | 0.040 |
Why?
|
| Education | 1 | 2019 | 22 | 0.040 |
Why?
|
| Disease Transmission, Infectious | 1 | 2019 | 39 | 0.040 |
Why?
|
| Limit of Detection | 1 | 2019 | 14 | 0.040 |
Why?
|
| Telomere | 1 | 2018 | 17 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2018 | 149 | 0.040 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2018 | 23 | 0.040 |
Why?
|
| Collagen Type I | 1 | 2018 | 6 | 0.040 |
Why?
|
| Point-of-Care Testing | 1 | 2019 | 71 | 0.040 |
Why?
|
| Specimen Handling | 1 | 2019 | 105 | 0.030 |
Why?
|
| Peptides | 1 | 2018 | 40 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 163 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2019 | 385 | 0.030 |
Why?
|
| Diet Surveys | 1 | 2017 | 7 | 0.030 |
Why?
|
| Nutrition Assessment | 1 | 2017 | 12 | 0.030 |
Why?
|
| Recommended Dietary Allowances | 1 | 2017 | 11 | 0.030 |
Why?
|
| Aged | 1 | 2022 | 1740 | 0.030 |
Why?
|
| Dyslipidemias | 1 | 2018 | 57 | 0.030 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2018 | 118 | 0.030 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2018 | 132 | 0.030 |
Why?
|
| Lost to Follow-Up | 1 | 2017 | 62 | 0.030 |
Why?
|
| Connective Tissue | 1 | 1977 | 1 | 0.030 |
Why?
|
| Self Report | 1 | 2017 | 114 | 0.030 |
Why?
|
| Potassium | 1 | 1977 | 25 | 0.030 |
Why?
|
| Foot | 1 | 2016 | 5 | 0.030 |
Why?
|
| Perinatal Care | 1 | 2016 | 21 | 0.030 |
Why?
|
| Sodium | 1 | 1977 | 30 | 0.030 |
Why?
|
| Calcium | 1 | 1977 | 49 | 0.030 |
Why?
|
| Infant, Low Birth Weight | 1 | 2016 | 35 | 0.030 |
Why?
|
| Gestational Age | 1 | 2016 | 80 | 0.030 |
Why?
|
| Infant, Premature | 1 | 2016 | 56 | 0.030 |
Why?
|
| African Americans | 1 | 2016 | 47 | 0.030 |
Why?
|
| Child Health Services | 1 | 2016 | 35 | 0.030 |
Why?
|
| Infant Mortality | 1 | 2016 | 97 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2018 | 317 | 0.030 |
Why?
|
| Haplotypes | 1 | 2016 | 125 | 0.030 |
Why?
|
| Molecular Sequence Data | 1 | 2015 | 263 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2014 | 38 | 0.030 |
Why?
|
| Health Services Research | 1 | 2014 | 58 | 0.030 |
Why?
|
| Sex Factors | 1 | 2014 | 227 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2013 | 133 | 0.020 |
Why?
|
| Alanine Transaminase | 1 | 2012 | 23 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 38 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 45 | 0.020 |
Why?
|
| Insulin Resistance | 1 | 2012 | 79 | 0.020 |
Why?
|
| Body Height | 1 | 2012 | 52 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2011 | 35 | 0.020 |
Why?
|
| pol Gene Products, Human Immunodeficiency Virus | 1 | 2011 | 29 | 0.020 |
Why?
|
| Ethionamide | 1 | 2010 | 9 | 0.020 |
Why?
|
| Isoniazid | 1 | 2010 | 110 | 0.020 |
Why?
|
| Microcirculation | 2 | 1975 | 5 | 0.010 |
Why?
|
| Rats | 2 | 1977 | 130 | 0.010 |
Why?
|
| Microelectrodes | 1 | 1977 | 1 | 0.010 |
Why?
|
| Extracellular Space | 1 | 1977 | 2 | 0.010 |
Why?
|
| Liver | 1 | 1977 | 74 | 0.010 |
Why?
|
| Blood Volume | 1 | 1975 | 1 | 0.010 |
Why?
|
| Hydrogen | 1 | 1975 | 1 | 0.010 |
Why?
|
| Liver Circulation | 1 | 1975 | 1 | 0.010 |
Why?
|
| Blood Viscosity | 1 | 1975 | 1 | 0.000 |
Why?
|
| Potentiometry | 1 | 1975 | 1 | 0.000 |
Why?
|
| Hematocrit | 1 | 1975 | 6 | 0.000 |
Why?
|
| Dogs | 1 | 1975 | 8 | 0.000 |
Why?
|
| Hypoxia | 1 | 1975 | 12 | 0.000 |
Why?
|
| Oxygen | 1 | 1975 | 25 | 0.000 |
Why?
|
| Hemodynamics | 1 | 1975 | 32 | 0.000 |
Why?
|